Cited 5 times in
Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 백용한 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 전재윤 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2015-05-19T17:36:18Z | - |
dc.date.available | 2015-05-19T17:36:18Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0300-5526 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/108464 | - |
dc.description.abstract | OBJECTIVE: High rate of resistance to lamivudine is a major problem in treating chronic hepatitis B (CHB) patients. We investigated the course of virologic breakthrough (VB) after emergence of YMDD mutants in CHB patients receiving lamivudine. METHODS: Ninety-three consecutive HBeAg-positive CHB patients treated with lamivudine (100 mg/day) who developed YMDD mutants and VB were enrolled. The clinical breakthrough (CB) was defined by elevation of alanine aminotransferase (ALT) >2 times the upper limit of normal. RESULTS: The median age was 47 years, and genotype of hepatitis B virus (HBV) was all C. The median duration of lamivudine administration was 39 months, and median pre-lamivudine ALT and HBV DNA were 165 IU/l and 1.2 x 10(8) copies/ml. In all patients, CB concurred with VB or appeared some months following VB. When patients were divided into two groups according to time sequence of two breakthroughs - group 1 (VB followed by CB, n = 68) and group 2 (concurrent VB and CB, n = 25)--there was no difference in patient and virologic characteristics between the two groups. The median time from VB to CB was 8 months in group 1. CONCLUSION: VB might eventually progress to CB in HBeAg-positive patients harboring YMDD mutants with high pretreatment ALT and HBV DNA. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 293~298 | - |
dc.relation.isPartOf | INTERVIROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Alanine Transaminase/blood | - |
dc.subject.MESH | Antiviral Agents/pharmacology | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Drug Resistance, Viral* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B virus/drug effects* | - |
dc.subject.MESH | Hepatitis B virus/genetics* | - |
dc.subject.MESH | Hepatitis B virus/isolation & purification | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic/physiopathology | - |
dc.subject.MESH | Hepatitis B, Chronic/virology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/pharmacology | - |
dc.subject.MESH | Lamivudine/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation, Missense* | - |
dc.subject.MESH | Viral Load | - |
dc.title | Clinical course of virologic breakthrough after emergence of YMDD mutations in HBeAg-positive chronic hepatitis B. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Yong Han Paik | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Chae Yoon Chon | - |
dc.identifier.doi | 10.1159/000170904 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A01829 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03544 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J01181 | - |
dc.identifier.eissn | 1423-0100 | - |
dc.identifier.pmid | 19001828 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/170904 | - |
dc.subject.keyword | Lamivudine | - |
dc.subject.keyword | Chronic hepatitis B | - |
dc.subject.keyword | Virologic breakthrough | - |
dc.subject.keyword | Clinical breakthrough | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Paik, Yong Han | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.alternativeName | Chon, Chae Yoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Paik, Yong Han | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Chon, Chae Yoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 51 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 293 | - |
dc.citation.endPage | 298 | - |
dc.identifier.bibliographicCitation | INTERVIROLOGY, Vol.51(4) : 293-298, 2008 | - |
dc.identifier.rimsid | 35593 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.